Loading company…
Suzhou Medilink Therapeutics develops antibody-drug conjugates and related drug candidates.
Founded in 2020 and based in Suzhou, China, Medilink Therapeutics develops antibody-drug conjugates using its TMALIN® platform. Candidates include L201, YL211, YL217, and YL242; YL211 is licensed globally to Roche. The company raised USD 70 million in Series B funding in March 2022 from Lyfe Capital, Qiming Venture Partners, Loyal Valley Capital, HighLight Capital, and Legend Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in